These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 10615856)

  • 21. Prodrugs in photodynamic anticancer therapy.
    Musiol R; Serda M; Polanski J
    Curr Pharm Des; 2011; 17(32):3548-59. PubMed ID: 22074426
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent Trends in
    Sun IC; Yoon HY; Lim DK; Kim K
    Bioconjug Chem; 2020 Apr; 31(4):1012-1024. PubMed ID: 32163277
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prodrug strategies in cancer therapy.
    Denny WA
    Eur J Med Chem; 2001; 36(7-8):577-95. PubMed ID: 11600229
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Strategies in the designing of prodrugs, taking into account the antiviral and anticancer compounds.
    Lesniewska-Kowiel MA; Muszalska I
    Eur J Med Chem; 2017 Mar; 129():53-71. PubMed ID: 28219047
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting and Treatment of Tumor Hypoxia by Newly Designed Prodrug Possessing High Permeability in Solid Tumors.
    Ikeda Y; Hisano H; Nishikawa Y; Nagasaki Y
    Mol Pharm; 2016 Jul; 13(7):2283-9. PubMed ID: 27187083
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activation of prodrugs by antibody-enzyme conjugates: a new approach to cancer therapy.
    Senter PD
    FASEB J; 1990 Feb; 4(2):188-93. PubMed ID: 2404820
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemical Reactivity Window Determines Prodrug Efficiency toward Glutathione Transferase Overexpressing Cancer Cells.
    van Gisbergen MW; Cebula M; Zhang J; Ottosson-Wadlund A; Dubois L; Lambin P; Tew KD; Townsend DM; Haenen GR; Drittij-Reijnders MJ; Saneyoshi H; Araki M; Shishido Y; Ito Y; Arnér ES; Abe H; Morgenstern R; Johansson K
    Mol Pharm; 2016 Jun; 13(6):2010-25. PubMed ID: 27093577
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates.
    Senter PD; Springer CJ
    Adv Drug Deliv Rev; 2001 Dec; 53(3):247-64. PubMed ID: 11744170
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Macromolecular Prodrugs Containing Organoiron-Based Compounds in Cancer Research: A Review.
    Mukaya EH; Mbianda XY
    Mini Rev Med Chem; 2020; 20(9):726-738. PubMed ID: 31702511
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular mechanisms of bufadienolides and their novel strategies for cancer treatment.
    Deng LJ; Li Y; Qi M; Liu JS; Wang S; Hu LJ; Lei YH; Jiang RW; Chen WM; Qi Q; Tian HY; Han WL; Wu BJ; Chen JX; Ye WC; Zhang DM
    Eur J Pharmacol; 2020 Nov; 887():173379. PubMed ID: 32758567
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exploiting Enzyme Alterations in Cancer for Drug Activation, Drug Delivery, and Nanotherapy.
    Hayashi JY; Tamanoi F
    Enzymes; 2017; 42():153-172. PubMed ID: 29054269
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy.
    Mowday AM; Ashoorzadeh A; Williams EM; Copp JN; Silva S; Bull MR; Abbattista MR; Anderson RF; Flanagan JU; Guise CP; Ackerley DF; Smaill JB; Patterson AV
    Biochem Pharmacol; 2016 Sep; 116():176-87. PubMed ID: 27453434
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy.
    Hay MP; Anderson RF; Ferry DM; Wilson WR; Denny WA
    J Med Chem; 2003 Dec; 46(25):5533-45. PubMed ID: 14640560
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prospects for hypoxia-activated anticancer drugs.
    Denny WA
    Curr Med Chem Anticancer Agents; 2004 Sep; 4(5):395-9. PubMed ID: 15379691
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selective cancer therapy by extracellular activation of a highly potent glycosidic duocarmycin analogue.
    Chen KC; Schmuck K; Tietze LF; Roffler SR
    Mol Pharm; 2013 May; 10(5):1773-82. PubMed ID: 23448264
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumour cytochrome P450 and drug activation.
    Patterson LH; Murray GI
    Curr Pharm Des; 2002; 8(15):1335-47. PubMed ID: 12052211
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzylphosphoramide mustards for E. coli nitroreductase activation.
    Jiang Y; Han J; Yu C; Vass SO; Searle PF; Browne P; Knox RJ; Hu L
    J Med Chem; 2006 Jul; 49(14):4333-43. PubMed ID: 16821793
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bioreductive therapies: an overview of drugs and their mechanisms of action.
    Rauth AM; Melo T; Misra V
    Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):755-62. PubMed ID: 9845091
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prodrug strategies in anticancer chemotherapy.
    Kratz F; Müller IA; Ryppa C; Warnecke A
    ChemMedChem; 2008 Jan; 3(1):20-53. PubMed ID: 17963208
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peptide conjugates of 4-aminocyclophosphamide as prodrugs of phosphoramide mustard for selective activation by prostate-specific antigen (PSA).
    Jiang Y; Hu L
    Bioorg Med Chem; 2013 Dec; 21(23):7507-14. PubMed ID: 24139844
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.